For patients with high-risk non–muscle-invasive bladder cancer (NMIBC), the gold-standard systemic therapy for preventing disease recurrence and progression following transurethral resection is ...
After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...
The PD-1 inhibitor sasanlimab showed anti-tumor activity and manageable safety in combination with BCG induction and maintenance compared with standard of care in patients with BCG-naïve high-risk ...
SUZHOU, China, Feb. 26, 2026 /PRNewswire/ -- Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG ...
It is important to note that several reviews carried out in England, Austria, the Czech Republic, and Japan are relatively old and the findings were useful for health decision makers of respective ...
Study findings fill in the evidence gap during the current BCG shortage, while data from randomized clinical trials are pending. Compared with bacillus Calmette-Guérin (BCG) therapy, sequential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results